A randomized, double blind, placebo-controlled, cross-over clinical trial, to assess the effects of candesartan (16/32 mg/d during 6 months) over metabolic, oxidative, and inflammatory parameters, in non-diabetic non-hypertensive subjects with dysglycemia and abdominal obesity.